Author: Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN
Year: 2019
AGREE II score: Unavailable
Developer organization: Canadian Urological Association
Type of cancer: Genitourinary, Prostate
Patient population: Adult
Location: Canada-wide
This clinical practice guideline is for patients with castration-resistant prostate cancer (CRPC). The guideline examines the management options available for these patients. Specific topics addressed include androgen-deprivation therapy (ADT), the addition or change of first-generation androgen receptor antagonists, and non-metastatic CRPC (nmCRPC).
